Scholarlink

Background <p>Lung Adenocarcinoma (LUAD) is a major subtype of Non-Small Cell Lung Cancer (NSCLC) with poor prognosis. Despite advances in molecular targeted therapy and immunotherapy, the five-year survival rate remains low. Disulfidptosis, a novel cell death mechanism, may play a role in tumor progression. <i>CD2AP</i> (CD2-associated protein), a key gene related to Disulfidptosis, is involved in cytoskeleton reorganization and signaling. This study aimed to explore <i>CD2AP</i>’s function in LUAD and its potential as a biomarker and therapeutic target through multi-omics analysis.</p> Methods <p>We analyzed <i>CD2AP</i> expression and clinical significance in LUAD using data from TCGA, GEO, and other public databases. We employed transcriptomics, methylation analysis, immune infiltration assays, and spatial transcriptomics. Kaplan–Meier survival analysis was used to assess the relationship between <i>CD2AP</i> expression and prognosis. Enrichment analysis identified biological processes and pathways related to <i>CD2AP</i>, while its association with the immune microenvironment and drug sensitivity was also evaluated.</p> Results <p><i>CD2AP</i> was significantly overexpressed in LUAD, and high expression correlated with poorer prognosis, including overall survival and progression-free survival. Enrichment analysis showed <i>CD2AP</i> is involved in cell adhesion, PI3K-Akt signaling, and immune escape, suggesting it promotes LUAD progression through these pathways. High <i>CD2AP</i> expression was associated with alterations in the tumor immune microenvironment and drug sensitivity, particularly to chemotherapeutics like Cisplatin, Etoposide, and Paclitaxel, and resistance to targeted therapies like Gefitinib. Spatial transcriptomics revealed higher <i>CD2AP</i> expression in tumor regions, especially in malignant cell-enriched areas.</p> Conclusion <p>This study highlights <i>CD2AP</i>'s critical role in LUAD, particularly in immune microenvironment modulation, metabolic reprogramming, and drug response. <i>CD2AP</i>'s high expression is linked to poor prognosis and may serve as a potential target for immunotherapy and drug response prediction.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of the disulfidptosis-related key gene CD2AP as a potential biomarker and new therapeutic target for LUAD patients by comprehensive multi-omics analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月11日

查看全文
  • Zhiwu Lin,
  • Jing Lv,
  • Chuanqiang Dai,
  • Yuanwei Zhai,
  • Jiudong Jiang,
  • Yang Gao,
  • Rulin Li,
  • Jiangang Fan,
  • Yang Yu,
  • Liang Wu,
  • Yanchun Yang

摘要

Background

Lung Adenocarcinoma (LUAD) is a major subtype of Non-Small Cell Lung Cancer (NSCLC) with poor prognosis. Despite advances in molecular targeted therapy and immunotherapy, the five-year survival rate remains low. Disulfidptosis, a novel cell death mechanism, may play a role in tumor progression. CD2AP (CD2-associated protein), a key gene related to Disulfidptosis, is involved in cytoskeleton reorganization and signaling. This study aimed to explore CD2AP’s function in LUAD and its potential as a biomarker and therapeutic target through multi-omics analysis.

Methods

We analyzed CD2AP expression and clinical significance in LUAD using data from TCGA, GEO, and other public databases. We employed transcriptomics, methylation analysis, immune infiltration assays, and spatial transcriptomics. Kaplan–Meier survival analysis was used to assess the relationship between CD2AP expression and prognosis. Enrichment analysis identified biological processes and pathways related to CD2AP, while its association with the immune microenvironment and drug sensitivity was also evaluated.

Results

CD2AP was significantly overexpressed in LUAD, and high expression correlated with poorer prognosis, including overall survival and progression-free survival. Enrichment analysis showed CD2AP is involved in cell adhesion, PI3K-Akt signaling, and immune escape, suggesting it promotes LUAD progression through these pathways. High CD2AP expression was associated with alterations in the tumor immune microenvironment and drug sensitivity, particularly to chemotherapeutics like Cisplatin, Etoposide, and Paclitaxel, and resistance to targeted therapies like Gefitinib. Spatial transcriptomics revealed higher CD2AP expression in tumor regions, especially in malignant cell-enriched areas.

Conclusion

This study highlights CD2AP's critical role in LUAD, particularly in immune microenvironment modulation, metabolic reprogramming, and drug response. CD2AP's high expression is linked to poor prognosis and may serve as a potential target for immunotherapy and drug response prediction.